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Poster Session II 137Conclusions:Kinetics of T-reg andT-cells engraftment were inde-
pendent, underlying the need for assessing chimerism levels among
each T-cells and T-regs in patients given nonmyeloablative condi-
tioning. Our data did not show any significant correlation between
T-reg levels and occurrence of chronic GVHD thus far. Data in-
cluding higher number of patients will be presented.374
PUVA THERAPY FOR ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) OF
THE SKIN
Furlong, T., Appelbaum, F.R., Carpenter, P.A., Deeg, J., Doney, K.,
Flowers, M.E.D., Kiem, H.-P., Martin, P.J., Mielcarek, M.,
Nash, R.A., Storb, R. Fred Hutchinson Cancer Research Center, Seattle,
WA.
Glucocorticoids remain the standard for initial treatment of acute
GVHD. However, toxicities and immunosuppression are severe
and steroid-sparing strategies would be desirable. Between 5/96
and 4/07 we treated 55 patients with isolated skin GVHDwith me-
thoxsalen plus ultraviolet-A light therapy (PUVA), with the objec-
tive of avoiding systemic immunosuppressive therapy. Patients
were treated with PUVA three times/week initially at doses of
0.25 J/m2, with exposure increased 0.25 J/m2 per treatment as clin-
ically indicated. The median patient age was 48 (range 4–71) years.
Twenty-six received a calcineurin inhibitor plus mycophenolate
mofetil for GVHD prophylaxis, 24 received a calcineurin inhibitor
plus methotrexate, and 5 received other regimens. Sixteen had re-
lated donors (1 HLA-mismatched), and 39 had unrelated donors
(15 HLA-mismatched). The median onset of GVHD was 26 days
after transplant, and the median start time of PUVA was 43 days.
Forty-five patients received PUVA as initial therapy for acute
GVHD, and 10 patients received PUVA for recurrent GVHD after
discontinuation of prednisone administration. At the start of PUVA
therapy, 31 patients (56%) had rash involving . 50% body surface
area (BSA), 19 (35%) had rash 26–50% BSA and 5 (9%) had rash#
25% BSA. The median number of PUVA treatments was 13 (range
2–26). Sixteen patients (29%) had complete responses after amedian
of 14 (range 8–26) PUVA treatments and required no subsequent
systemic immunosuppressive therapy for treatment of acute
GVHD. Twelve patients required systemic therapy after starting
PUVA for treatment of isolated gastrointestinal GVHD, although
8 of these patients had cleared or improved skin rash before starting
systemic therapy. Twenty-four patients (44%) required systemic
immunosuppressive therapy after starting PUVA for treatment of
skinGVHD (18) or skin plus gastrointestinal GVHD (6). Three pa-
tients had evidence of skin GVHD when PUVA was discontinued
early due to readmission to the hospital or discharge home. Only
four patients required secondary systemic therapy for treatment of
acute GVHD.Thirty-one of 52 patients who could be evaluated de-
veloped chronicGVHD.Thirty-seven patients remain alive at ame-
dian of 753 days after transplant. Overall, 24 of 55 patients (44%)
responded to PUVAwith resolution or improvement of rash. These
results suggest that PUVA can be effective in treating skin GVHD
and in reducing the need for systemic immunosuppressive treat-
ment.375
THE ANALYSIS OF CHRONIC GVHD AFTER CORD BLOOD TRANSPLANTA-
TION IN COMPARISON WITH BONE MARROW TRANSPLANTATION
Seo, S., Uchida, N., Yamamoto, H., Takagi, S., Tsuji, M., Kato, D.,
Matsuno, N., Masuoka, K., Wake, A., Taniguchi, S. Toranomon Hospi-
tal, Tokyo, Japan.
Backgrounds: Umbilical cord blood can be an alternative stem
cell source for the patients with hematological malignancies requir-
ing allogeneic stem cell transplantation. However, little is known
about graft versus leukemia/lymphoma (GVL) effect in cord blood
transplantation (CBT). Here, we analyzed chronic GVHD
(cGVHD) in CBT compared with that in BMT and evaluated the
relevance between cGVHD andGVL.Patients/Methods:We ret-rospectively studied 162 patients who had been free from disease
progression for more than 100 days after either unrelated BMT (n
5 75) or CBT (n 5 87) at Toranomon Hospital from January
2002 to December 2006. Median age of the patients was 52 years
old (BMT vs CBT: 49 vs 53). Underlying diseases were acute leuke-
mia (n 5 88), myelodysplastic syndrome (n 5 17), lymphoma (n 5
39) and others (n 5 18). Conditioning regimens were mainly com-
posed of Fludarabine 125–180 mg/m2 with several combinations of
Melphalan 80–140 mg/m2, Busulfan 8–16 mg/kg and/or total body
irradiation (4–8 Gy).Results:TheMedian observation period after
the transplantationwas 612 days (range, 109–1944). The cumulative
incidence of cGVHD was 84% in BMT and 62% in CBT (p 5
0.09). The severity of cGVHD was analyzed based on its type; lim-
ited or extensive. In CBT, the percentage of the former type was
34% (vs 25% in BMT) and the latter was 23% (vs 48% in BMT).
High-risk disease (p 5 0.03) and preceding acute GVHD(p 5
0.03) are related to the occurrence of cGVHD. RICBT tended to
increase cGVHD compared to CBT using BU/CY or CY/TBI reg-
imen. Multivariative analysis showed that cGVHD increased over-
all survival rate (p\0.01) and suppressed recurrence of the disease
(p\0.01). During observation period, no patients after CBT were
died of cGVHD. Discussion: We demonstrated that cGVHD in
CBT is tolerable compared with that in BMT and that the occur-
rence of cGVHD could result in good prognosis. Our analysis
also suggested that CBT could have GVL effect as well as BMT.376
PERSISTENT RECIPIENT ANTIGEN-PRESENTING CELLS IN HUMAN HE-
MATOPOIETIC STEM CELL TRANSPLANTATION: IDENTIFICATION OF
A DERMAL SUBSET THAT OUTLIVES EPIDERMAL LANGERHANS CELLS
Haniffa, M.1, Ginhoux, F.2, Abel, M.2, Bullock, S.1, Alshemali, S.1,
Merad, M.2, Collin, M.P.1,2. 1Newcastle University, Newcastle upon
Tyne, United Kingdom; 2Mount Sinai School of Medicine, New York.
Graft versus host disease (GVHD), a lethal complication of he-
matopoietic stem cell transplantation (HSCT), is initiated by recip-
ient antigen presenting cells (APC) priming donorT cells. The skin,
a commonly affected organ, contains diverse APC including hetero-
geneous dermal dendritic cells (DC) whose contribution to GVHD
is not well understood.
We have obtained 22 pairs of skin biopsies pre and post condi-
tioning (high dose BuCy or CyTBI and reduced intensity Flu/
Mel) and 85 biopsies at day 40, 100 and 365 post HSCT from pa-
tients with sex-mismatched donors. Pre and post conditioning sam-
ples were digested and analysed with CD45, HLA-DR, CD14 and
CD1a antibodies in a single step Trucount protocol. Chimerism
was determined on cytospins of spontaneously migrated dermal
APC and collagenase digested dermal cells using sequential four-
colour confocal microscopy and X/Y fluorescence in situ hybridiza-
tion.
We find 3 populations of CD451 DR1 dermal cells: CD141
CD1a- fXIIIa-; CD141 CD1a- fXIIIa1; CD1a1 CD14- fXIIIa-.
Characterization of these cells in vitro shows that CD141 cells
are more adherent and phagocytic than CD1a1 cells and that the
fXIIIa1 component is in addition, heavily granulated with ingested
melanin. CD141 APC are resistant to depletion by conditioning
(210 pre/213 post; cells per mm2; P 0.86) compared with CD1a1
cells (201 pre/97 post; mean cells per mm2; P 0.03). Both are re-
duced in HSCT patients compared with controls (706 CD141
and 468 CD1a1 cells per mm2; both P 0.01).
Chimerism analysis at 40, 100 and 365 days post HSCT reveals
two strikingly different patterns of engraftment. CD1a1 and
CD141 fXIIIa- cells, obtained either bymigration or digestion, en-
graft rapidly in all patients, ahead of LC, reaching medians of 99%
and 100% donor, respectively, at day 40. In contrast, CD141
fXIIIa1 cells, which are obtained only from digested dermis, are
very slow to engraft in the absence of GHVD, reaching only 63%
median donor after high dose and 10%median donor chimerism af-
ter reduced regimens, at 1 year. Acute GVHD promotes engraft-
ment with 100% donor chimerism seen in nearly all patients at
day 100. Cell cycle analysis ndicates that these cells are not actively
synthesizing DNA, suggesting a different mode of survival com-
pared with persistent recipient LC.
138 Poster Session IIIn conclusion, we have identified a subset of human dermal APC
with protracted survival after HSCT and potential importance in
promoting donor T cell reactivity to host antigens.377
LOW DOSE ANTI-THYMOCYTE GLOBULIN FOR GRAFT-VERSUS-HOST
DISEASE PROPHYLAXIS OF MISMATCHED UNRELATED PERIPHERAL
BLOOD STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH
ACUTE MYELOGENOUS LEUKEMIA
Kim, H.-J., Min, W.-S., Eom, K.-S., Cho, B.-S., Min, C.-K., Lee, S.,
Cho, S.-G., Lee, J.-W., Kim, C.-C. Catholic HSCT Center, St. Mary’s
Hospital Catholic University of Korea College of Medicine, Seoul, Republic
of Korea.
Anti-thymocyte globulin (ATG) has been introduced in prevent-
ing acute graft-versus-host disease (AGvHD) in several studies.
Many of them suggest that ATG at a total dose range of 4.515
mg/kg reduces the risk of severe AGvHD but increases the risk of
infections. We tried to investigate the role of ATG in HLA-mis-
matched unrelated hematopoietic stem cell transplantations
(uHSCT), specifically in patients who received G-CSF mobilized
peripheral blood stem cells (PBSCs) or from allele(s)/antigen mis-
matched unrelated donors from worldwide donor registries. Sixty
five patients with intermediate to unfavourable risk AML who re-
ceived HLA-mismatched uHSCT from the available Asian as well
as Caucasian donors were enrolled. We compared 2 different
groups according to the use of ATG (group 1) or not (group 2).
The addition of ATG (thymoglobulin, Genzyme), at a dose of
1.25 mg per kilogram of body weight per day for 2 consecutive
days, for recipients who received either PBSCs and/or from mis-
matched unrelated donors (group 1, N5 35); this was added to pre-
vent the development of AGvHD together with our standard
regimen which consisted of methotrexate (10 mg/m2 intravenously
bolus on day11; andmethotrexate 5mg/m2 intravenously bolus, on
days 13, 16, 111) and tacrolimus starting at day –1. G-CSF was
administered in all patients at a dose of 5 mg/kg subcutaneously
per day from D1 7 after transplantation until neutrophil recovery.
The median age was 38 (range, 16–65) and the median follow-up
duration was 24 months (range, 3–72). The majority of patients
had intermediate or unfavourable cytogenetic features. The main
conditioning regimen consisted in cyclophosphamide plus total
body irradiation. The transplanted patients were all successfully en-
grafted. The median time to neutrophil (.0.5  109/kg) and plate-
let (.20  109/kg) recovery was 15 vs 17 days, 14 vs 17 days in the
group 1 and 2, respectively. The overall incidence of AGvHD and
chronic GvHD was 38% and 41%; 33% and 35%, 37% and 48%
for patients with group 1 and group2, respectively. Nine (14%) pa-
tients were relapsed so far. The comparison of estimated probability
of disease-free survival rate at 2-year for each group was 89% vs
74%, respectively. The estimated probability of event-free survival
rate at 2-year was 65% vs 51%, respectively. The overall 2-year
non-relapse TRMwas 14%. These results suggest that the uHSCT
performed with a very low dose of ATG (total 2.5 mg/kg) are feasi-
ble with a promising outcome.378
TACROLIMUS, SIROLIMUS AND ANTITHYMOCYTE GLOBULIN (rATG)
FOR GRAFT VERSUS HOST DISEASE PROPHYLAXIS FOR UNRELATED DO-
NOR HEMATOPOIETIC CELL TRANSPLANTATION
Aljitawi, O.S., Nakamura, R., Palmer, J., Senitzer, D., Pullarkat, V.,
Briggs, A., Cai, J.-L., Rosenthal, J., Schriber, J., Snyder, D.,
Nademanee, A., Parker, P., Forman, S. City of Hope Comprehensive
Cancer Center, Duarte, CA.
The effect of adding ATG to Tacrolimus/Sirolimus combination
in graft-versus-host disease (GVHD) prophylaxis is largely un-
known.We reviewed our records for patients who underwent unre-
lated transplants and received this combination for GVHD
prophylaxis. Nineteen patients were identified who received their
transplants between 8/06 and 02/07. Median age at time of trans-plant was 51.1 years (17–61.5). Nine recipients were males and 10
were females. The indications for transplant were as follows: ALL
n 5 9, AML n 5 5, NHL n 5 2, MDS n 5 2 and CML n 5 1.
Twelve patients were in remission (CR1 5 10, $CR2: n 5 2),
and seven had refractory disease. Eight patients received reduced-
intensity conditioning (fludarbine/melphalan: n 5 8) and 11 re-
ceived full-intensity conditioning (FTBI/VP-16: n 5 8, FTBI/Cy-
toxan: n5 3). All received peripheral blood hematopoietic stem cell
products except for two patients who received bone marrow prod-
ucts with the median CD341cell dose of 6.82 (1.56–9.46) x106/
Kg. Donors were molecularly matched in A, B, C, and DR in 11 pa-
tients; the remaining donors were mismatch in class I (n 5 5) or
both class I and II (n 5 3). After a median follow-up of 9 months
16 patients are alive. Two deaths were related to infections within
the first hundred days and not associated with acute GVHD. One
patient died of relapsed AML. The probabilities of one-year overall
survival, disease-free survival, relapse, and non-relapse mortality
were 78%, 80%, 11%, and 11%, respectively. Ten patients devel-
oped acute GVHD with median onset of 24 days (7–35 days) after
transplantation including five (26%) grade II and two (11%) grade
III. We observed no grade IV GVHD in this cohort. Two patients
developed chronic GVHD (limited: n 5 1, extensive: n 5 1). Pa-
tients tolerated rATG treatment well except for one who developed
atrial fibrillation. Three patients developed thrombotic microangi-
opathy that required discontinuation of tacrolimus and sirolimus.
Six of 15 CMV seropositive recipients developed reactivation of
CMV including one with CMV pneumonia. None had reactivation
of EBV. Eight patients had at least one documented bacterial infec-
tion.
Conclusion: In conclusion, the combination of Tacrolimus/siro-
limus/rATG appears to be well tolerated, with a low rate of acute
GVHD in this high risk group of patients without increased risk
of early relapse or CMV/EBV reactivation. A prospective trial of
this new combination in unrelated donor transplants is underway
at our institution.379
INTRA-ARTERIAL CATHETER DIRECTED IMMUNOSUPPRESSIVE THER-
APY FOR STEROID RESISTANT OR DEPENDENT GRAFT VS. HOST DIS-
EASE (GVHD)
Shapira, M.Y.1, Bloom, A.I.2, Or, R.1, Resnick, I.B.1, Aker, M.1,
Bitan,M.1, Slavin, S.1, Verstandig, A.2. 1Hadassah – HebrewUniversity
Medical Center, Jerusalem, Israel; 2Hadassah – HebrewUniversityMed-
ical Center, Jerusalem, Israel.
Introduction: Prolonged treatment of graft vs. host disease
(GVHD) is extremely immunosuppressive. Local therapy with in-
tra-arterial (IA) injection of steroids may induce remission with
lower extent of systemic immune suppression. Here, we present
our experience with IA treatment of gastrointestinal (GI) and/or he-
patic steroid resistant/dependent GVHDwith 2 consecutive proto-
cols.Methods:Thirty five patients (37 GVHD events (hepatic, n5
15), (GI, n 5 16), (combined, n 5 6)) were treated with 53 IA ses-
sions. Results: We found that IA steroid therapy was associated
with partial and complete remission among patients with steroid re-
sistant/dependent hepatic or GI GVHD. Hepatic partial response
was observed in 14 (66.6%) patients among whom 7 (33.3%)
reached complete response. GI partial response was observed in
19 (86.4%) patients among whom 12 (54.4%) reached complete re-
sponse.Most side effects were minor. An early administration of the
local therapy, female gender, myeloid basic disease, and a non-ac-
tive status of the basic disease at the day of transplantation were
found related for predicting a better response for the intra-arterial
treatment. The use of high dose steroids in the hepatic IA protocol
from was at least as good as intermediate dose steroids with meth-
otrexate and may be safer. Conclusion: Intra-arterial catheter
guided steroid therapy is safe and effective in steroid resistant/de-
pendent GVHD. Hepatic artery treatment with methotrexate can
be safely substituted with high dose IAmethylprednisolone. Further
research is warranted characterizing the patients benefit most.
